Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benign prostatic hyperplasia: a review.

E W Ramsey1

  • 1Section of Urology, University of Manitoba and Health Sciences Centre, Winnipeg, Manitoba, Canada.

The Canadian Journal of Urology
|January 11, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia.

Surgical technology international·2011
Same author

Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.

The Journal of urology·2005
Same author

Transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia: results obtained with the Urologix T3 device.

World journal of urology·2002
Same author

Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder.

The Journal of urology·2001
Same author

Durability of results obtained with transurethral microwave thermotherapy in the treatment of men with symptomatic benign prostatic hyperplasia.

Journal of endourology·2000
Same author

Practice patterns of Canadian urologists in benign prostatic hyperplasia and prostate cancer. Canadian Prostate Health Council.

The Journal of urology·2000
Same journal

Smarter, Not More: The Rationale for Reducing Systematic Cores in the MRI-Targeted Biopsy Era.

The Canadian journal of urology·2026
Same journal

Ten Years of Progress in Advanced Prostate Cancer at the AUA.

The Canadian journal of urology·2026
Same journal

Electroacupuncture for sperm improvement in varicocele: a case report.

The Canadian journal of urology·2026
Same journal

Transperineal approach for penetrating injury of corpus spongiosum and bulbous urethra caused by vesicourethral foreign body: a case report.

The Canadian journal of urology·2026
Same journal

Penile fracture and concomitant severe urethral trauma-a case report and discussion of surgical approach.

The Canadian journal of urology·2026
Same journal

Management of retained bullet fragments from posterior urethra after gunshot wound: a case report.

The Canadian journal of urology·2026
See all related articles

Benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms (LUTS) with unpredictable progression. Treatment choices for BPH-related LUTS balance symptom relief, quality of life, and potential harms.

Area of Science:

  • Urology
  • Men's Health
  • Geriatrics

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition in aging men.
  • Lower urinary tract symptoms (LUTS) are frequently associated with BPH.
  • BPH significantly impacts quality of life for affected individuals.

Purpose of the Study:

  • To review the natural history of BPH.
  • To outline current evaluation strategies for LUTS in BPH.
  • To discuss management options for BPH-induced LUTS.

Main Methods:

  • Comprehensive review of existing literature on BPH.
  • Analysis of current clinical guidelines for BPH management.
  • Synthesis of data on treatment efficacy and outcomes.

Related Experiment Videos

Main Results:

  • The natural history of symptomatic BPH is highly variable.
  • Factors like symptom severity, age, and prostate size predict urinary retention risk.
  • Alpha-blockers are common first-line therapy; watchful waiting is suitable for mild symptoms.
  • Transurethral resection of the prostate (TURP) remains a primary surgical option.

Conclusions:

  • BPH primarily affects patient quality of life.
  • Treatment decisions for BPH require careful consideration of benefits, harms, and patient preferences.
  • Management strategies should be individualized based on treatment availability and patient-physician agreement.